Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.

@article{Michelson2001AtomoxetineIT,
  title={Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study.},
  author={D. Michelson and Douglas E. Faries and Jakob Wernicke and Douglas Kelsey and Kristin Kendrick and Floyd R. Sallee and Thomas Spencer},
  journal={Pediatrics},
  year={2001},
  volume={108 5},
  pages={E83}
}
OBJECTIVE Atomoxetine is an investigational, nonstimulant pharmacotherapy being studied as potential treatment for attention-deficit/hyperactivity disorder (ADHD). It is thought to act via blockade of the presynaptic norepinephrine transporter in the brain. We assessed the efficacy of 3 doses of atomoxetine compared with placebo in children and adolescents with ADHD. METHODS A total of 297 children and adolescents who were 8 to 18 years of age and had ADHD as defined by the Diagnostic and… CONTINUE READING
Highly Influential
This paper has highly influenced 29 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
194 Citations
21 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 194 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Efficacy of atomoxetine vs . placebo in pediatric outpatients with ADHD

  • J Heiligenstein, T Spencer, DE Faries
  • Biological Psychiatry .
  • 2001

Subjective responses to LY 139603 ( Atomoxetine ) and Methylphenidate [ abstract 70 ]

  • HF Laws, SH Heil, WK Bickel, ST Higgins, DE Faries
  • J Fam Pract
  • 1999

Similar Papers

Loading similar papers…